semax mastery course
Unit 7 of 11

chemistry and pharmacokinetics

the amino acid sequence, modifications, and intranasal PK profile

a deliberately stabilized fragment

Semax's structure is deceptively simple: seven amino acids (Met-Glu-His-Phe-Pro-Gly-Pro) where the first four come from ACTH and the last three are the stabilizing PGP extension. Community modifications like N-Acetyl Semax Amidate (NASA) add further chemical groups but lack clinical data. The intranasal PK profile explains both onset and duration.

structure comparison tool

explore the interactive visualization for this unit.

structure comparison tool

semax at a glance

key structural and pharmacokinetic numbers from clinical data.

~813 Da
molecular weight -- small enough for intranasal absorption without penetration enhancers
7 residues
Met-Glu-His-Phe (ACTH 4-7 core) + Pro-Gly-Pro (stability extension)
>16x stability
PGP extension increases serum half-life vs unmodified ACTH(4-10) -- >80% intact after 60 min
60-70%
intranasal bioavailability -- peak plasma at 5-15 min, CSF at 30-45 min
All structure-activity and PK data below comes from Russian pharmaceutical studies and in vitro serum stability assays. NASA (N-Acetyl Semax Amidate) is a community modification with zero published pharmacological data -- its properties cannot be inferred from standard Semax clinical evidence.

key terms

definitions you will encounter throughout this unit.

P pharmacophore chemistry
The minimum set of structural features in a molecule that are responsible for its biological activity. For Semax, the His-Phe dipeptide at positions 3-4 is the minimum pharmacophore for cognitive effects, though potency increases substantially with the full Met-Glu-His-Phe tetrapeptide.
P PGP extension modification
Pro-Gly-Pro -- the three amino acid C-terminal extension added to ACTH(4-7) to create Semax. The proline residues resist aminopeptidase and carboxypeptidase attack, while glycine at position 6 acts as a molecular hinge that preserves the active core's shape. The extension itself (as the tripeptide PGP) may have independent biological activity as a neutrophil chemoattractant.
B bioavailability pharmacokinetics
The fraction of a drug dose that reaches systemic circulation unchanged. Semax achieves 60-70% bioavailability via intranasal delivery, which is excellent for a peptide -- oral delivery typically gives less than 1% for peptides because stomach acid and digestive enzymes destroy them.
O olfactory cleft pathway delivery
A direct nose-to-brain transport route where molecules travel along olfactory nerve fibers from the upper nasal cavity into the CNS, bypassing the blood-brain barrier. This pathway partially explains Semax's rapid cognitive onset (CSF levels peak at 30-45 minutes) despite being a peptide that wouldn't normally cross the BBB efficiently.
N NASA community variant
N-Acetyl Semax Amidate -- a community-developed modification that adds an acetyl group to the N-terminal methionine and an amide group to the C-terminal proline. These modifications target the two most vulnerable degradation points. NASA has zero published clinical, animal, or formal in vitro data -- all claims about it must be evaluated completely separately from standard Semax evidence.

semax chemistry -- the simple version

what the molecule looks like and why it was built that way.

Semax is a short chain of seven amino acids (the building blocks of all proteins) arranged in a specific order: Met-Glu-His-Phe-Pro-Gly-Pro. The first four come from a natural brain hormone called ACTH, which your body already uses to regulate stress and cognition. Researchers in Russia took just the part of ACTH responsible for cognitive benefits and threw away the part that raises cortisol (a stress hormone). The problem was that this small fragment broke down in the body within minutes. To fix that, they added a three-amino-acid tail called Pro-Gly-Pro (PGP) that acts like a protective cap, making the peptide last hours instead of minutes. The result is a molecule small enough to absorb through the nose and stable enough to reach the brain.

A advanced: why Met-Glu-His-Phe is the active core term
The Met-Glu-His-Phe tetrapeptide corresponds to positions 4-7 of the 39-amino-acid ACTH hormone. Decades of structure-activity research showed that this fragment retains the cognitive and neuroprotective properties of full ACTH while completely lacking the hormonal activity that drives cortisol release. The His-Phe dipeptide at positions 3-4 of the fragment is the absolute minimum pharmacophore for any detectable cognitive activity, but potency increases substantially with the full four-residue core. This is why Semax preserves all four residues rather than trimming further.
advanced: how PGP resists enzymatic degradation
Proline is unusual among amino acids because its side chain loops back and bonds to the backbone nitrogen, creating a rigid kink that peptidases (enzymes that break peptide bonds) struggle to cleave. By placing proline at both ends of the extension and glycine as a flexible hinge in the middle, the PGP tail shields the vulnerable C-terminus of the ACTH core from carboxypeptidases without distorting the active region's three-dimensional shape. The same PGP strategy was used to stabilize Selank (tuftsin + PGP), confirming its general utility for intranasal neuropeptide delivery.
advanced: N-Acetyl Semax Amidate (NASA) modifications
NASA adds an acetyl group to the N-terminal methionine and an amide group to the C-terminal proline, targeting the two remaining degradation-vulnerable sites on Semax. Acetylation blocks aminopeptidase attack at the front of the chain, and amidation neutralizes the free carboxyl group at the back. While these are well-established peptide chemistry techniques, NASA has zero published clinical, animal, or formal in vitro data. It is a community-developed modification whose pharmacological profile must be evaluated entirely separately from the clinically characterized standard Semax compound.

intranasal pharmacokinetic timeline

from drop to brain -- the absorption and activity cascade.

Semax follows a distinct pharmacokinetic timeline after intranasal administration. The peptide is absorbed through two parallel routes: systemic absorption through the richly vascularized nasal mucosa (~160 cm2 surface area) and direct nose-to-brain transport via the olfactory and trigeminal nerve pathways.

Peak plasma concentrations are reached within 5-15 minutes, while CSF levels peak at 30-45 minutes -- consistent with the dual absorption pathway. The effective cognitive duration is 4-6 hours based on EEG and behavioral measurements, though BDNF upregulation may persist for 24 hours or longer.

The 0.1% solution delivers approximately 50 mcg per drop for cognitive use, while the 1% solution delivers 500 mcg per drop for acute stroke -- a 10-fold concentration difference reflecting distinct clinical objectives. The peptide is cleared primarily through renal excretion after peptidase degradation into inactive amino acid fragments.

Methionine oxidation at position 1 is the primary stability concern during storage. Exposure to air, light, or heat accelerates this degradation and reduces biological activity -- proper refrigeration (2-8 degrees C) and light protection are critical for maintaining potency in both pharmaceutical and reconstituted formulations.

Intranasal delivery works for Semax precisely because of its molecular weight. At ~813 Da, the heptapeptide is small enough to cross the nasal mucosa via paracellular and transcellular routes without penetration enhancers, and small enough to use the olfactory and trigeminal nerve pathways for direct nose-to-brain transit. Peptides much above ~1000 Da typically require permeation enhancers or alternative delivery routes -- Semax sits comfortably below that ceiling.

ACTH to Semax, residue by residue

how the cognitive fragment was trimmed and then stabilized.

peptide derivation chain
ACTH(4-10)
  1. 4
    Met
  2. 5
    Glu
  3. 6
    His
  4. 7
    Phe
  5. 8
    Arg
  6. 9
    Trp
  7. 10
    Gly
ACTH(4-7) core
  1. 1
    Met
  2. 2
    Glu
  3. 3
    His
  4. 4
    Phe
Semax
  1. 1
    Met
  2. 2
    Glu
  3. 3
    His
  4. 4
    Phe
  5. 5
    Pro
  6. 6
    Gly
  7. 7
    Pro
ACTH(4-7) cognitive core Pro-Gly-Pro stability extension

where this has been studied

structural, pharmacokinetic, and synthesis evidence -- mostly Russian, with limited Western replication.

NMR / X-ray structural studies
Russian crystallography and solution-NMR groups characterized Semax's three-dimensional conformation, showing the PGP tail adopts a polyproline II-like helix that shields the cognitive core. Crystal structures of the free heptapeptide are limited, and there is no published co-crystal of Semax bound to a receptor.
intranasal PK in healthy humans
Small studies in healthy adult volunteers reported plasma Cmax at 5-15 minutes, Tmax in the same window, and AUC values consistent with ~60-70% bioavailability via the nasal route. CSF levels peaked at 30-45 minutes, supporting the dual systemic + nose-to-brain absorption pathway.
plasma protein binding / metabolism
In-vitro studies in human plasma and microsomes characterized Semax as having low plasma protein binding and being cleared primarily by aminopeptidase-mediated hydrolysis. The resulting fragments are inactive amino-acid scraps and short di- and tripeptides that are renally excreted.
Fmoc SPPS synthesis route
Semax is manufactured by standard Fmoc solid-phase peptide synthesis (SPPS). Validation studies confirmed reproducible scale-up at multi-gram levels with high purity by HPLC. The methionine at position 1 requires controlled handling to avoid oxidation, which is the dominant degradation pathway during synthesis and storage.

Semax vs Selank vs NASA

sequence, modification, expected half-life, and clinical evidence tier compared side-by-side.

Semax

  • Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (ACTH(4-7) + PGP)
  • Modification position: C-terminal PGP extension
  • Expected half-life: hours intranasally; minutes for free fragment
  • Clinical evidence tier: Russian MoH approval; Phase III data exists in Russian

Selank

  • Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (tuftsin + PGP)
  • Modification position: C-terminal PGP extension (same template as Semax)
  • Expected half-life: hours intranasally; tuftsin alone clears in minutes
  • Clinical evidence tier: Russian MoH approval (2009) for generalized anxiety disorder

NASA

  • Sequence: N-acetyl-Met-Glu-His-Phe-Pro-Gly-Pro-NH2 (Semax with both termini capped)
  • Modification position: N-terminal acetyl + C-terminal amide
  • Expected half-life: hypothetically longer than Semax; not measured
  • Clinical evidence tier: none -- community modification, zero published clinical data